{
    "clinical_study": {
        "@rank": "166415", 
        "arm_group": {
            "arm_group_label": "Treatment (brentuximab vedotin)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies brentuximab vedotin in treating patients with advanced\n      systemic mastocytosis or mast cell leukemia. Monoclonal antibodies, such as brentuximab\n      vedotin, can block cancer growth in different ways. Some block the ability of cancer cells\n      to grow and spread. Others find cancer cells and help kill them or carry cancer-killing\n      substances to them"
        }, 
        "brief_title": "Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia", 
        "condition": [
            "Aggressive Systemic Mastocytosis", 
            "Mast Cell Leukemia", 
            "Systemic Mastocytosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Aggression", 
                "Leukemia", 
                "Leukemia, Mast-Cell", 
                "Mastocytosis", 
                "Urticaria Pigmentosa", 
                "Mastocytosis, Systemic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To evaluate the response rate to SGN-35 (brentuximab vedotin) in patients with tumor\n      necrosis factor receptor superfamily, member 8 (CD30+) advanced systemic mastocytosis (SM)\n      (ASM or mast cell leukemia [MCL] with or without an associated hematological clonal non-mast\n      cell lineage disease [AHNMD]).\n\n      SECONDARY OBJECTIVES:\n\n      I. To evaluate the tolerability and safety profile of SGN-35 in patients with SM.\n\n      II. To evaluate expression of CD30 on neoplastic mast cells before and during therapy with\n      SGN-35.\n\n      III. To evaluate changes in mastocytosis related symptom scores and quality of life (QOL)\n      using a modified Myeloproliferative Neoplasm Symptom Assessment Form (MPNSAF).\n\n      IV. To evaluate the duration of response (DoR) and time to response (TTR). V. To evaluate\n      progression-free survival (PFS).\n\n      OUTLINE:\n\n      Patients receive brentuximab vedotin intravenously (IV) over 30 minutes on day 1. Treatment\n      repeats every 21 days for 8 courses in the absence of disease progression or unacceptable\n      toxicity.\n\n      After completion of study treatment, patients are followed up every 6 weeks for 1 year and\n      then every 12 weeks thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must give written informed consent\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-3\n\n          -  Life expectancy > 12 weeks\n\n          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper\n             limit of normal (ULN), if caused by ASM/MCL =< 5 x ULN\n\n          -  Serum direct bilirubin =< 1.5 x ULN; if considered related to ASM/MCL =< 3 x ULN\n\n          -  Serum creatinine =< 2.0 mg/dL\n\n          -  A diagnosis of systemic mastocytosis (SM) per 2008 World Health Organization (WHO)\n             Criteria\n\n          -  Neoplastic mast cells must express CD30 by immunohistochemistry or flow cytometry\n\n          -  Patients with ASM and MCL with or without an AHNMD are required to have at least one\n             of the eligible organ damage findings as defined by the international consensus\n             response criteria\n\n          -  Both females of childbearing potential and males who have partners of childbearing\n             potential must agree to use an effective contraceptive method during the study and\n             for 30 days following the last dose of study drug\n\n          -  Females of childbearing potential must have a negative serum or urine beta-human\n             chorionic gonadotropin (hCG) pregnancy test result within 7 days prior to the first\n             dose of SGN-35; females of non-childbearing potential are those who are\n             postmenopausal greater than 1 year or who have had a bilateral tubal ligation or\n             hysterectomy\n\n        Exclusion Criteria:\n\n          -  Patients unwilling or unable to comply with the protocol\n\n          -  Any other concurrent severe known disease (except carcinoma in-situ) or concurrent\n             severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, or active\n             uncontrolled infection) which could compromise participation in the study\n\n          -  History of another primary malignancy that has not been in remission for at least 3\n             years (the following are exempt from the 3-year limit: non-melanoma skin cancer,\n             fully excised melanoma in situ [stage 0], curatively treated localized prostate\n             cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion\n             on Papanicolaou [PAP] smear)\n\n          -  Patients with cardiovascular disease including congestive heart failure grade III or\n             IV according to the New York Heart Association (NYHA) classification, left\n             ventricular ejection fraction of < 50%, myocardial infarction within previous 6\n             months or poorly controlled hypertension\n\n          -  Women who are pregnant or lactating\n\n          -  Patients with >= grade 2 neuropathy\n\n          -  Patients with a known hypersensitivity to any excipient contained in the drug\n             formulation\n\n          -  Confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral\n             hepatitis\n\n          -  Patients presenting with an AHNMD requiring immediate cytoreductive therapy or\n             targeted drugs (e.g. AML)\n\n          -  Patients who have received any investigational agent, chemotherapy, interferon-alfa,\n             or 2-chlorodeoxyadenosine (2-CdA, cladribine) within 30 days prior to Day 1\n\n          -  Patients who have received hematopoietic growth factor support within 14 days of Day\n             1 of SGN-35\n\n          -  Use of prednisone (or equivalent corticosteroid dose) for SM up to 10 mg/day or its\n             equivalent is allowed, but it cannot have been started during screening; patients who\n             are on prednisone up to 10 mg/day for medical problems unrelated to SM are also\n             permitted on study\n\n          -  Patients with the FIP1L1-PDGFRalpha fusion even with resistance to imatinib (such\n             patients are no longer defined as systemic mastocytosis by the WHO)\n\n          -  Patients who have received any treatment with SGN-35 prior to study entry\n\n          -  Patients who have had any surgical procedure, excluding central venous catheter\n             placement or other minor procedures (e.g. skin biopsy) within 14 days of Day 1"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01807598", 
            "org_study_id": "HEMMPD0016", 
            "secondary_id": "NCI-2013-00537"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (brentuximab vedotin)", 
                "description": "Given IV", 
                "intervention_name": "brentuximab vedotin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Adcetris", 
                    "anti-CD30 ADC SGN-35", 
                    "anti-CD30 antibody-drug conjugate SGN-35", 
                    "antibody-drug conjugate SGN-35", 
                    "SGN-35"
                ]
            }, 
            {
                "arm_group_label": "Treatment (brentuximab vedotin)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment (brentuximab vedotin)", 
                "description": "Ancillary studies", 
                "intervention_name": "quality-of-life assessment", 
                "intervention_type": "Procedure", 
                "other_name": "quality of life assessment"
            }, 
            {
                "arm_group_label": "Treatment (brentuximab vedotin)", 
                "description": "Ancillary studies", 
                "intervention_name": "questionnaire administration", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies, Monoclonal", 
                "Immunoconjugates"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Jason R. Gotlib", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Study of Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis With or Without an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD)", 
        "overall_contact": {
            "email": "hkaur@stanford.edu", 
            "last_name": "Harshdeep Kaur", 
            "phone": "650-723-3589"
        }, 
        "overall_official": {
            "affiliation": "Stanford University Hospitals and Clinics", 
            "last_name": "Jason Gotlib", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Will be estimated and its 95% confidence interval will be provided.", 
            "measure": "Overall response rate per consensus international response criteria (rate of complete or partial remissions or clinical improvement)", 
            "safety_issue": "No", 
            "time_frame": "Up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01807598"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Immunohistochemical expression of CD30 on neoplastic mast cells in core biopsy samples by flow cytometry", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "measure": "Total symptom score using a modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "description": "The Kaplan-Meier product-limit method will be used to summarize.", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Time from first onset of confirmed response to the date of first documented and confirmed progression or death, assessed up to 1 year"
            }, 
            {
                "description": "The Kaplan-Meier product-limit method will be used to summarize.", 
                "measure": "Time to response", 
                "safety_issue": "No", 
                "time_frame": "Time from start of treatment until the date of onset of  a confirmed response, assessed up to 1 year"
            }, 
            {
                "description": "The Kaplan-Meier product-limit method will be used to summarize.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Time from start of treatment to the date of the first documented and confirmed progression or death or institution of new therapy, assessed up to 1 year"
            }, 
            {
                "measure": "Type of adverse events measured by National Cancer Institute Common Toxicity Criteria  (NCI CTC) version 4.03", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "measure": "Quality of life (QOL) score using a modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "measure": "Incidence of adverse events measured by National Cancer Institute Common Toxicity Criteria  (NCI CTC) version 4.03", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "measure": "Severity of adverse events measured by National Cancer Institute Common Toxicity Criteria  (NCI CTC) version 4.03", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "measure": "Seriousness of adverse events measured by National Cancer Institute Common Toxicity Criteria  (NCI CTC) version 4.03", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "measure": "Relatedness of adverse events measured by National Cancer Institute Common Toxicity Criteria  (NCI CTC) version 4.03", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }
        ], 
        "source": "Stanford University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}